Literature DB >> 25863853

Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study.

Celine E Saade1, Hamed B Lari2, Tamara L Berezina2, Robert D Fechtner2, Albert S Khouri3.   

Abstract

OBJECTIVE: To evaluate the association between the intensity and duration of glaucoma topical therapy and severity of signs and symptoms of ocular surface disease (OSD).
DESIGN: Single-site, prospective, controlled, cross-sectional study. PARTICIPANTS: Sixty-one patients with no diagnosis of or previous treatment for OSD were identified.
METHODS: Patients were assigned to 2 groups: the glaucoma group with 31 patients diagnosed with primary open-angle glaucoma and using at least 1 topical intraocular pressure (IOP)-lowering medication and the control group including 30 patients with no diagnosis of glaucoma or history of topical therapy usage. The right eye of each patient was arbitrarily chosen. Each patient completed an Ocular Surface Disease Index (OSDI) questionnaire and underwent evaluation of the ocular surface by conjunctival and corneal lissamine green (LG) staining and tear breakup time (TBUT). The intensity index (drops/wk × therapy duration in years) was calculated to quantify the topical therapy.
RESULTS: OSDI scores of the glaucoma group correlated to the intensity index (r = 0.46, CI 0.13-0.69). The glaucoma group had a higher mean OSDI score than the control group (18.97 ± 9.5 versus 6.25 ± 5.7, p = 5.85E-08). Abnormal TBUT and LG staining scores were prevalent in the glaucoma group compared with the control group (68% vs 17%, p = 0.000078; 65% vs 3%, p = 2.9E-07).
CONCLUSIONS: Patients on glaucoma therapy have a greater prevalence of OSD symptoms, and their intensity index correlates to the OSDI score. The intensity index reflects quantitatively the amount of treatment and can be further validated in future studies as a predicting tool for OSD development.
Copyright © 2015 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25863853     DOI: 10.1016/j.jcjo.2014.11.006

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  8 in total

1.  Relationship between OSDI questionnaire and ocular surface changes in glaucomatous patients.

Authors:  Adriano Guarnieri; Elena Carnero; Anne-Marie Bleau; Belén Alfonso-Bartolozzi; Javier Moreno-Montañés
Journal:  Int Ophthalmol       Date:  2019-12-07       Impact factor: 2.031

2.  Risk Factors for Ocular Surface Disease in Tunisian Users of Preserved Antiglaucomatous Eye Drops.

Authors:  Houda Lajmi; Wassim Hmaied; Besma Ben Achour; Amin Zahaf
Journal:  J Curr Ophthalmol       Date:  2021-07-05

3.  Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients.

Authors:  Ngamkae Ruangvaravate; Karnthida Choojun; Benjawan Srikulsasitorn; Jatupol Chokboonpiem; Dechathon Asanatong; Supaporn Trakanwitthayarak
Journal:  Clin Ophthalmol       Date:  2020-10-07

4.  Ocular lubricant use in medically and surgically treated glaucoma: a retrospective longitudinal analysis.

Authors:  Jayant Venkatramani Iyer; Yang Zhao; Fiona Pin Miao Lim; Louis Tong; Tina Tzee Ling Wong
Journal:  Clin Ophthalmol       Date:  2017-06-23

5.  Correlation of Ocular Surface Disease and Quality of Life in Indian Glaucoma Patients: BAC-preserved versus BAC-free Travoprost.

Authors:  Suresh Kumar; Tanu Singh; Parul Ichhpujani; Sanchi Vohra; Sahil Thakur
Journal:  Turk J Ophthalmol       Date:  2020-04-29

6.  Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost.

Authors:  Suresh Kumar; Tanu Singh; Parul Ichhpujani; Sanchi Vohra
Journal:  Rom J Ophthalmol       Date:  2019 Jul-Sep

7.  Evaluation of Adverse Effects of Topical Glaucoma Medications on Trabeculectomy Outcomes Using the Glaucoma Medications Intensity Index.

Authors:  Jasper Ka Wai Wong; Tsz Kin Leung; Jimmy Shiu-Ming Lai; Jonathan Cheuk-Hung Chan
Journal:  Ophthalmol Ther       Date:  2021-12-21

8.  Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease.

Authors:  Sang-Woo Park; Jiwoong Lee; Michael S Kook
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.